FDA approves groundbreaking standalone use of Spravato for depression treatment

The FDA has taken a historic step by approving Spravato (esketamine nasal spray) for standalone use in treating major depressive disorder (MDD) and related psychiatric disorders, including post-traumatic stress disorder (PTSD). This approval marks a major shift in treatment options, particularly for patients who have not responded to conventional therapies.

Previously approved only with oral antidepressants
Until now, Spravato was only approved for use alongside traditional oral antidepressants. With this latest decision, the FDA has allowed Spravato to be prescribed and administered on its own, a milestone that could change the treatment landscape for those with severe, treatment-resistant depression.

Mechanism and safety profile of esketamine
Spravato contains esketamine, a derivative of the anesthetic ketamine. This innovative treatment targets the brain’s glutamate pathway, which plays a key role in mood regulation. Although the exact mechanism is not fully understood, ketamine-based therapies have shown significant promise in rapidly relieving depression symptoms. According to the FDA, the safety profile of standalone Spravato is consistent with previous data from combined treatments.

Clinical trial data and findings
The FDA’s approval followed an in-depth review of clinical trial data. Results showed that 22.5% of patients who received Spravato experienced notable improvement in depressive symptoms, compared to just 7.6% in the placebo group. The agency confirmed that no significant new safety concerns emerged, and the findings aligned with previous research.

Administration process and side effects
Spravato will be administered under professional supervision in clinical settings, where patients will be monitored for a short period after treatment. Reported side effects include temporary nausea, vomiting, and fatigue. Patients are advised not to drive themselves home after treatment. Other possible side effects include short-term increases in blood pressure, confusion, and bladder issues.